Last $1.36 USD
Change Today +0.07 / 5.43%
Volume 556.3K
ATHX On Other Exchanges
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

athersys inc (ATHX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/9/14 - $4.33
52 Week Low
04/28/14 - $1.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ATHERSYS INC (ATHX)

Related News

No related news articles were found.

athersys inc (ATHX) Related Businessweek News

No Related Businessweek News Found

athersys inc (ATHX) Details

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which has Phase I clinical trials for the patients that have suffered an acute myocardial infarction, and leukemia or other blood-borne cancers; and is ongoing Phase II clinical trials for the patients suffering from inflammatory bowel disease (IBD) and ischemic stroke. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing small pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

56 Employees
Last Reported Date: 03/13/14
Founded in 1995

athersys inc (ATHX) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $568.8K
President, Chief Operating Officer and Secret...
Total Annual Compensation: $455.4K
Co-Founder, Chief Scientific Officer, Executi...
Total Annual Compensation: $452.9K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $281.3K
Executive Vice President of Regenerative Medi...
Total Annual Compensation: $383.0K
Compensation as of Fiscal Year 2013.

athersys inc (ATHX) Key Developments

Athersys, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Athersys, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $293,000 against $621,000 a year ago, reflecting primarily a decrease in grant revenue. Loss from operations was $7,268,000 against $5,604,000 a year ago. Net loss was $4,719,000 against $5,614,000 a year ago. The difference reflects the impact of a $2.5 million increase in non-cash income from the change in the fair value of warrant liabilities, less the $1.3 million aggregate increase in research and development and general and administrative expenses, and the $0.3 million decrease in revenues. Diluted net loss per share was $0.08 against $0.10 a year ago. During the nine-month period ended September 30, 2014, cash used in operating activities was $19.7 million and was $18.3 million in the comparable period of 2013.

Athersys, Inc. Presents at Drexel Hamilton Micro-Cap Investor Forum 2014, Nov-13-2014 09:00 AM

Athersys, Inc. Presents at Drexel Hamilton Micro-Cap Investor Forum 2014, Nov-13-2014 09:00 AM. Venue: Drexel Hamilton's offices, 77 Water Street Downtown, New York, New York, United States.

Athersys, Inc. to Report Q3, 2014 Results on Nov 10, 2014

Athersys, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 10, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATHX:US $1.36 USD +0.07

ATHX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cytori Therapeutics Inc $0.51 USD -0.0061
NeoStem Inc $3.34 USD +0.09
Nuo Therapeutics Inc $0.36 USD +0.043
Pluristem Therapeutics Inc $2.50 USD -0.01
StemCells Inc $0.96 USD -0.0287
View Industry Companies

Industry Analysis


Industry Average

Valuation ATHX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 45.6x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 31.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATHERSYS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at